Short Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - April 14, 2023) - Humanigen, Inc. (Nasdaq: HGEN), Humanigen Australia Pty Ltd, (Humanigen) and the South Australian Health ...

Lenzilumab's mechanism of action has already been de-risked to some degree in COVID-19-associated respiratory distress by clinical trials conducted with other GM-CSF blockade antibodies.

“Lenzilumab is one of the few Phase 3 treatment options in development for COVID-19, and we believe that its mechanism of action as an immunomodulator could work very nicely with remdesivir ...

BURLINGAME, CA/ ACCESSWIRE/ April 2, 2020/ Humanigen, Inc.,, a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company's proprietary ...

NEW YORK and LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune ...

Lenzilumab will be evaluated in combination with remdesivir and compared to placebo and remdesivir; July 27, 2020 04:05 PM Eastern Daylight Time. ... given the differing mechanisms of action. ...

Positive interim results were announced from a phase 3 study evaluating lenzilumab, an investigational anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody, for the ...

Humanigen Inc (OTCQB:HGEN) presented findings Tuesday showing that a cohort of 12 patients with coronavirus-associated pneumonia treated with its drug... This website uses cookies. We use cookies to ...

Lenzilumab is an investigational anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody. The EUA application included data from the phase 3 LIVE-AIR trial (ClinicalTrials ...

Humanigen's monoclonal antibody lenzilumab significantly increased survival without the use of mechanical ventilation among hospitalized COVID-19 patients, according to a study published Dec. 1 in ...

Company Provides Drug Free of Charge to Several Leading Centers BURLINGAME, CA / ACCESSWIRE / April 2, 2020 / Humanigen, Inc., (OTCQB:HGEN) ("Humanigen"), a clinical stage biopharmaceutical ...

Humanigen's monoclonal antibody lenzilumab significantly increased survival without the use of mechanical ventilation among hospitalized COVID-19 patients, according to a study published Dec. 1 in ...